Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Keskin, Onur; Wedemeyer, Heiner; Tuzun, Ali; Zachou, Kalliopi; Deda, Xheni; Dalekos, George; Heidrich, Benjamin; Pehlivan, Selcen; Zeuzem, Stefan; YALÇIN, KENDAL; GÜREL, SELİM; TABAK, Ömer; İDİLMAN, RAMAZAN; Bozkaya, Hakan; Manns, Michael; Yurdaydin, Cihan

doi:10.1016/j.cgh.2015.05.029

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Keskin O., Wedemeyer H., Tuzun A., Zachou K., Deda X., Dalekos G. N., ...Daha Fazla

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, cilt.13, sa.13, ss.2342-2351, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 13
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.cgh.2015.05.029
Dergi Adı: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2342-2351
Anahtar Kelimeler: Chronic Delta Hepatitis, Pegylated Interferon Treatment, Treatment Outcome Prediction, On-Treatment HDV RNA, CHRONIC DELTA-HEPATITIS, PEGINTERFERON ALPHA-2A, KINETICS, INTERLEUKIN-28B, POLYMORPHISMS, RIBAVIRIN, EFFICACY, HBSAG, DRUG
Ankara Üniversitesi Adresli: Evet

Özet

BACKGROUND & AIMS: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international study of hepatitis D treatment to identify factors associated with outcomes of pegylated interferon treatment, with and without adefovir.